CONNECTA Therapeutics has announced the launch of its pediatric development program for CTH120, a groundbreaking treatment for Fragile X Syndrome, supported by a €2.5M EIC grant.

Spinogenix announces collaboration with FRAXA Research Foundation to advance Phase 2b trial of SPG601, aimed at treating Fragile X Syndrome.

Spinogenix reveals full Phase 2a trial results for SPG601, a pioneering treatment for Fragile X Syndrome, showcasing promising cognitive improvements.

Servier's acquisition of KER-0193, a potential treatment for Fragile X syndrome, marks a pivotal step in expanding its neurology pipeline aimed at rare diseases.

Servier has recently acquired KER-0193, a promising treatment for Fragile X syndrome, enhancing its neurology pipeline with innovative therapies.

Kaerus Bioscience's lead candidate KER-0193 receives Orphan Drug and Rare Pediatric Drug Designations from the FDA for treating Fragile X syndrome.

Spinogenix announces promising results from its Phase 2 study of SPG601 for treating Fragile X syndrome, showing potential to improve quality of life.

The FDA's Fast Track designation for Spinogenix's SPG601 marks significant progress in developing a treatment for Fragile X syndrome, a key cause of autism.